Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Increase in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDXGet Free Report) saw a large increase in short interest in January. As of January 30th, there was short interest totaling 25,685 shares, an increase of 57.9% from the January 15th total of 16,265 shares. Based on an average daily volume of 166,115 shares, the short-interest ratio is presently 0.2 days. Currently, 3.6% of the company’s stock are sold short. Currently, 3.6% of the company’s stock are sold short. Based on an average daily volume of 166,115 shares, the short-interest ratio is presently 0.2 days.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BJDX shares. Wall Street Zen raised shares of Bluejay Diagnostics to a “sell” rating in a research report on Saturday, November 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Check Out Our Latest Stock Report on BJDX

Bluejay Diagnostics Stock Down 1.8%

BJDX stock opened at $2.67 on Monday. The firm has a market cap of $1.90 million, a PE ratio of -0.01 and a beta of 0.66. The business has a 50 day moving average of $3.15 and a 200-day moving average of $5.49. Bluejay Diagnostics has a 12-month low of $2.51 and a 12-month high of $40.80.

Bluejay Diagnostics Company Profile

(Get Free Report)

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.

See Also

Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.